Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Clinical trial NCT00526136 · COMPLETED

Trial details

NCT number: NCT00526136
Sponsor: Advanz Pharma
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Atrial Fibrillation

Start date: 2007-03-01
Enrollment: 735

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.